A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Devalingam Mahalingam; Sanjay Goel; Santiago Aparo; Sukeshi Patel Arora; Nicole Noronha; Hue Tran; Romit Chakrabarty; Giovanni Selvaggi; Andres Gutierrez; Matthew Coffey; Steffan Nawrocki; Gerard Nuovo; Monica Mita

doi:10.3390/cancers10060160

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Devalingam Mahalingam, Sanjay Goel, Santiago Aparo, Sukeshi Patel Arora, Nicole Noronha, Hue Tran, Romit Chakrabarty, Giovanni Selvaggi, Andres Gutierrez, Matthew Coffey, Steffan Nawrocki, Gerard Nuovo, Monica Mita

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancers
Volume	10
DOIs	https://doi.org/10.3390/cancers10060160
State	Published - May 25 2018

Disciplines

Medicine and Health Sciences
Oncology
Immunology and Infectious Disease

Access to Document

10.3390/cancers10060160License: Unspecified

Cite this

@article{7b1bfbeceed74b39ac3b15daeac0dbc0,

title = "A Phase II Study of Pelareorep (REOLYSIN{\textregistered}) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma",

author = "Devalingam Mahalingam and Sanjay Goel and Santiago Aparo and Arora, {Sukeshi Patel} and Nicole Noronha and Hue Tran and Romit Chakrabarty and Giovanni Selvaggi and Andres Gutierrez and Matthew Coffey and Steffan Nawrocki and Gerard Nuovo and Monica Mita",

note = "Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone ...",

year = "2018",

month = may,

day = "25",

doi = "10.3390/cancers10060160",

language = "American English",

volume = "10",

journal = "Cancers",

}

TY - JOUR

T1 - A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

AU - Mahalingam, Devalingam

AU - Goel, Sanjay

AU - Aparo, Santiago

AU - Arora, Sukeshi Patel

AU - Noronha, Nicole

AU - Tran, Hue

AU - Chakrabarty, Romit

AU - Selvaggi, Giovanni

AU - Gutierrez, Andres

AU - Coffey, Matthew

AU - Nawrocki, Steffan

AU - Nuovo, Gerard

AU - Mita, Monica

N1 - Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, with 1 and 5-year survival rates of ~18% and 7% respectively. FOLFIRINOX or gemcitabine in combination with nab-paclitaxel are standard treatment options for metastatic disease. However, both regimens are more toxic than gemcitabine alone ...

PY - 2018/5/25

Y1 - 2018/5/25

UR - https://pubmed.ncbi.nlm.nih.gov/29799479/

U2 - 10.3390/cancers10060160

DO - 10.3390/cancers10060160

M3 - Article

VL - 10

JO - Cancers

JF - Cancers

ER -

A Phase II Study of Pelareorep (REOLYSIN®) in Combination with Gemcitabine for Patients with Advanced Pancreatic Adenocarcinoma

Disciplines

Access to Document

Other files and links

Cite this